V

Vor Biopharma Inc
NASDAQ:VOR

Watchlist Manager
Vor Biopharma Inc
NASDAQ:VOR
Watchlist
Price: 10.58 USD -9.11%
Market Cap: 231.8m USD

Vor Biopharma Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vor Biopharma Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
V
Vor Biopharma Inc
NASDAQ:VOR
Net Income (Common)
-$116.9m
CAGR 3-Years
-19%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Vor Biopharma Inc
Glance View

Market Cap
231.8m USD
Industry
Biotechnology

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 135 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. VOR33 is the lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. The company is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML. The company offers VCAR33 programs that are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33.

VOR Intrinsic Value
Not Available
V

See Also

What is Vor Biopharma Inc's Net Income (Common)?
Net Income (Common)
-116.9m USD

Based on the financial report for Dec 31, 2024, Vor Biopharma Inc's Net Income (Common) amounts to -116.9m USD.

What is Vor Biopharma Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-56%

Over the last year, the Net Income (Common) growth was 1%. The average annual Net Income (Common) growth rates for Vor Biopharma Inc have been -19% over the past three years , -56% over the past five years .

Back to Top